Skip Nav Destination
.jpeg?versionId=9918)
President's Column
Lessons Learned in a Year Like No Other
"Looking ahead to 2026, my hope is that we will see a renewed appreciation for the role of scientific research and celebrate new treatment breakthroughs, Together, I believe we will make progress," writes ASH President Belinda R. Avalos, MD in her final column.
Diagnostic Oversights in Underrecognized Hemoglobin Variants
Hemoglobinopathies are among the most common inherited red blood cell disorders, yet they remain underrecognized in routine clinical practice.
Is This the Way?
Arm D of the SEQUOIA study is one of the few cohorts to evaluate the efficacy of a cBTKi and venetoclax doublet in a patient population enriched for those with p53 aberrations.
VERONA and the Future of High-Risk Myelodysplastic Syndromes
VERONA may not have delivered the patient benefit that the MDS patients, advocates, and clinicians had hoped for, but it has provided crucial insights.
